Beckman Coulter has announced that it will be combining Agencourt Bioscience and the newly acquired Cogenics to Beckman Coulter Genomics.
Beckman Coulter has announced that it will be combining Agencourt Bioscience and the newly acquired Cogenics to form Beckman Coulter Genomics. The new company is expected to offer researchers a single genomic services resource with expanded global capabilities.
"Through the creation of Beckman Coulter Genomics, we have successfully brought together the industry's leading genomic service providers to offer our customers the highest quality data and analysis," said Richard Creager, PhD, Beckman Coulter group vice president of immunoassay, molecular diagnostics and genomic services, in a statement.
Services currently available through the new company are reported to include sequencing, sample preparation, genotyping, gene expression, biological efficiency and safety testing, with support for all levels of regulatory compliance, including Clinical Laboratory Improvement Amendments (CLIA).
The new company has offices throughout North America and Europe.
For more information about Beckman Coulter Genomics visit www.beckmangenomics.com, www.agencourt.com and www.cogenics.com
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.